Table 2.
Ki67 analysis as a continuous variable: Multivariable Cox proportional hazard models for RFS, OS, and DSS.
Model | Factor | Comparison | Hazard Ratio | 95% LCL | 95% UCL | Overall p-value |
---|---|---|---|---|---|---|
RFS Model 1 (N = 634, #Events = 281) | Ki67% weighted average | 1% increase | 1.07 | 1.03 | 1.11 | 0.0008 |
Margin | Pos vs. Neg | 1.41 | 1.09 | 1.84 | 0.01 | |
Seminal vesicle invasion | Yes vs. No | 1.85 | 1.23 | 2.80 | 0.003 | |
Gleason score | 3+4 vs. 6 | 1.22 | 0.90 | 1.66 | 0.005 | |
4+3 vs. 6 | 1.88 | 1.33 | 2.66 | |||
8–10 vs. 6 | 1.42 | 0.96 | 2.09 | |||
Pathologic stage | pT3/pT4 vs. pT2 | 1.43 | 1.07 | 1.92 | 0.02 | |
Log(PSA) | 1 unit increase | 1.62 | 1.35 | 1.96 | <.0001 | |
RFS Model 2 (N = 634, #Events = 281) | Ki67% maximum | 1% increase | 1.04 | 1.01 | 1.07 | 0.007 |
Margin | Pos vs. Neg | 1.40 | 1.08 | 1.83 | 0.01 | |
Seminal vesicle invasion | Yes vs. No | 1.85 | 1.22 | 2.79 | 0.004 | |
Gleason score | 3+4 vs. 6 | 1.24 | 0.91 | 1.67 | 0.003 | |
4+3 vs. 6 | 1.91 | 1.35 | 2.70 | |||
8–10 vs. 6 | 1.46 | 0.99 | 2.15 | |||
Pathologic stage | pT3/pT4 vs. pT2 | 1.44 | 1.07 | 1.93 | 0.02 | |
Log(PSA) | 1 unit increase | 1.61 | 1.34 | 1.95 | <.0001 | |
OS (N = 984, #Events = 57) | Ki67% positive | 1% increase | 1.09 | 1.01 | 1.16 | 0.02 |
Gleason Score | 3+4 vs. <=6 | 0.87 | 0.44 | 1.72 | 0.68 | |
4+3 vs. <=6 | 1.14 | 0.46 | 2.84 | 0.78 | ||
8–10 vs. <=6 | 3.28 | 1.65 | 6.51 | 0.0007 | ||
DSS (N = 874, #Events = 44) | Ki67% positive | 1% increase | 1.10 | 1.02 | 1.18 | 0.02 |
Log(PSA) | 1 unit increase | 1.98 | 1.35 | 2.89 | 0.005 | |
Gleason Score | 3+4 vs. <=6 | 2.27 | 0.93 | 5.52 | 0.07 | |
4+3 vs. <=6 | 2.75 | 0.97 | 7.81 | 0.06 | ||
8–10 vs. <=6 | 5.13 | 1.92 | 13.75 | 0.001 |
Recurrence free survival (RFS) event is defined as any recurrence, metastasis, or prostate cancer death. Models 1 and 2 are separate models using Ki67 weighted average % positive (PI=2.19) and maximum % positive (PI=3.11), respectively. Overall survival (OS) event is defined as death of any cause. Disease-specific survival (DSS) event is defined as prostate cancer metastasis or death due to PC. Both OS and DSS have only one final model. Only significant factors were included in the final models.